

Product Name: Nisoldipine Revision Date: 01/17/2022 Product Data Sheet

Nisoldipine

Cat. No.:	B1989		Contraction of the second
CAS No.:	63675-72-9		HN-
Formula:	C20H24N2O6		
M.Wt:	388.41		por
Synonyms:			
Target:	Membrane Transporter/Ion C	hannel	0
Pathway:	Calcium Channel		
Storage:	Store at -20°C		
	EN ^o		

Solvent & Solubility

	insoluble in H2O; \geq 10.62 mg/mL in EtOH; \geq 11.55 mg/mL in DMSO					
In Vitro	Preparing Stock Solutions	Mass Solvent Concentration	1mg	5mg	10mg	
		1 mM	2.5746 mL	12.8730 mL	25.7460 mL	
		5 mM	0.5149 mL	2.5746 mL	5.1492 mL	
		10 mM	0.2575 mL	1.2873 mL	2.5746 mL	

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary

calcium channel blocker

IC50 & Target

In Vitro

get		esto esto
	Cell Viability Assay	DE Front Market
	Cell Line:	Guinea-pig ventricular myocytes
	Preparation method:	The solubility of this compound in DMSO is > 11.6 mg/mL. General tips for
		obtaining a higher concentration: Please warm the tube at 37 $^\circ\mathrm{C}$ for 10 minutes
		and/or shake it in the ultrasonic bath for a while. Stock solution can be stored
		below - 20 °C for several months.
	Reacting conditions:	10 ~ 100 µM; 8 ~ 10 mins

1 | www.apexbt.com

	Applications:	In guinea-pig ventricular myocytes, Nisoldipine inhibited rapidly activating
		delayed-rectifier K+ current (I(Kr)) with an IC50 value of 23 $\mu\text{M},$ as well a
		slowly activating delayed-rectifier K+ current (I(Ks)) with an IC50 value of 4
		μM . It was estimated that Nisoldipine is approximately 30 times more selective
	BLO	for L-type Ca2+ channels than for delayed-rectifier K+ channels.
	Animal experiment	P E Contra
In Vivo	Animal models:	A dog model of coronary ischemia-reperfusion
	Dosage form:	6.6 μg/kg/min; i.v.
	Applications:	Compared with the control group, the Nisoldipine treatment group showe
		similar hemodynamic measurements. However, mass of necrosis and mass
		risk was obviously lower in the Nisoldipine group. In a dog model of coronal
		ischemia-reperfusion, Nisoldipine reduced the infarct size.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility ma
		slightly differ with the theoretical value. This is caused by an experimenta
	En common	system error and it is normal.
	Control Entrol	Calor, Ergen
	Constant and a second	

Product Citations

See more customer validations on www.apexbt.com.

References

Bloom

PERBIC

[1]. Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T. The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol. 1998 Nov;125(5):1005-12.

[2]. Missan S1, Zhabyeyev P, Dyachok O, Jones SE, McDonald TF. Block of cardiac delayed-rectifier and inward-rectifier K+ currents by nisoldipine. Br J Pharmacol. 2003 Nov;140(5):863-70.

[3]. Hammerman H, Moscovitz M, Hir J. Beneficial effect of nisoldipine in repeated coronary reperfusion. Coron Artery Dis. 1997 Feb;8(2):97-100.

Caution

FOR RESEARCH PURPOSES ONLY. NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

2 | www.apexbt.com





APExBIO Technology www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com











